Profile
Sector:
HealthcareCountry:
IsraelIPO:
31 May 2013Website:
http://www.kamada.comNext earnings report:
16 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 32 min agoDividend
Analysts recommendations
Institutional Ownership
KMDA Latest News
Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ET
Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company has announced an expanded commercial agreement for its anti-rabies drug Kedrab including a minimum revenue guarantee for the next four years. The new deal significantly derisks the Kamada investment case by locking in growth for one of the company's largest revenue streams.
Kamada Ltd. has potential catalysts for growth, capital attraction and regulatory tailwinds. The company's valuation appears attractive, with forward estimates suggesting a possible re-rating. Key risks center around the investment in 2x new manufacturing facilities in its Israeli footprint.
Kamada Ltd. (NASDAQ:KMDA ) Q1 2023 Results Earnings Conference Call May 24, 2023 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors, LLC Amir London - Chief Executive Officer Conference Call Participants David Bautz - Zacks Small Cap Research Operator Greetings and welcome to the Kamada Ltd.
REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2023, prior to the open of the U.S. financial markets on Wednesday, May 24, 2023.
What type of business is Kamada?
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
What sector is Kamada in?
Kamada is in the Healthcare sector
What industry is Kamada in?
Kamada is in the Drug Manufacturers - Specialty & Generic industry
What country is Kamada from?
Kamada is headquartered in Israel
When did Kamada go public?
Kamada initial public offering (IPO) was on 31 May 2013
What is Kamada website?
https://www.kamada.com
Is Kamada in the S&P 500?
No, Kamada is not included in the S&P 500 index
Is Kamada in the NASDAQ 100?
No, Kamada is not included in the NASDAQ 100 index
Is Kamada in the Dow Jones?
No, Kamada is not included in the Dow Jones index
When does Kamada report earnings?
The next expected earnings date for Kamada is 16 August 2024